Anti-diabetic Agents and the Potentials for Reducing Cardiovascular Risks in Type-2 Diabetes Mellitus

Recent reports from Cardiovascular Outcome Trials (CVOTs) revealed that some newer anti-diabetic drugs impact Major Adverse Cardiovascular Events (MACE). These medications include the Sodium-Glucose Co-Transporter (SGLT2) inhibitors and the Glucagon-like Peptide-1 (GLP-1) receptor agonists. There is...

Full description

Bibliographic Details
Main Authors: Ezeani IU, Eregie A, Ohwovoriole AE
Format: Article
Published: Medical and Dental Consultants Association of Nigeria, OOUTH Sagamu 2021-09-01
Series:Annals of Health Research
Online Access: